Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data
Tesamorelin (Egrifta SV) is approved to reduce excess abdominal fat in HIV-associated lipodystrophy and has formal prescribing information, warnings, and monitoring expectations
In addition to its role in glucose metabolism, GLP-1 reduces appetite and food intake
Feeling emotionally blunt or like a zombie, where you feel neither happy nor sad, is often a sign of over-medication
How long is the drive from North Shields
Pickup currently not available Cagrilintide is a long-acting amylin receptor agonist for laboratory investigation of satiety signalling and metabolic pathway modulation